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background: The benefit of Implanted Cardioverter Defibrillators (ICD) for primary prevention of sudden cardiac death (SCD) has been well 
established in patients with nonischemic dilated cardiomyopathy (NIDCM). However, the frequency of appropriate ICD therapy delivery in the subset 
of patients with peripartum cardiomyopathy (PPCM) has not been studied.
methods: Retrospective case control analysis was performed on 19 women with PPCM who had ICD implant for primary prevention of SCD at Henry 
Ford Hospital between 1996 and 2012. Trained specialists in electrophysiology adjudicated all device shocks. Wilcoxon rank sum test was used to 
test for differences in appropriate ICD utilization between the test group and a control group of 60 women with primary prevention ICD for NIDCM.
results: Results are outlined in Table 1. Subjects with PPCM were younger than controls, but well matched in all other measured variables, 
including months of follow up, left ventricular ejection fraction and programmed cutoff for therapy delivery. Overall, women with PPCM had a non-
significant trend toward greater utilization of appropriate ICD therapy compared to controls.
conclusions: Women with PPCM who meet criteria for ICD implant for primary prevention of SCD are at least as likely to receive appropriate 
therapies for ventricular tachyarrhythmias as women with primary prevention ICD for NIDCM, with a trend toward higher utilization. Our data suggests 
that this group likely represents a high-risk subset of women with NIDCM.
Table 1. Demographic and Outcome Data of the Study and Control Groups
Peripartum Cardiomyopathy (N=19) Control Group (N=60) p value
Demographics
Age ( years) 32 ± 5.9 56.8 ± 12.8 < 0.0001
LVEF at implant (%) 20.6 ±10.8 22.5 ± 9.5 0.47
Months of followup 35.9 ± 34.7 29.3 ± 27.2 0.39
Minimum ICD threshold for therapy delivery (bpm) 186.7 ± 15.7 190.2 ± 10.1 0.37
Clinical Events
Patients who received appropriate therapy (%) 7 ( 36.8%) 12 (20%) 0.22
Appropriate shocks per patient 0.84 ± 1.98 0.57 ± 2.13 0.34
